

# Hao Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7351403/publications.pdf>

Version: 2024-02-01

74  
papers

7,312  
citations

186209

28  
h-index

95218

68  
g-index

76  
all docs

76  
docs citations

76  
times ranked

8237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Epidermal Growth Factor Receptor 2 (HER2) â€“Specific Chimeric Antigen Receptorâ€“Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1688-1696.	0.8	778
2	Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. <i>Blood</i> , 2010, 115, 925-935.	0.6	721
3	HER2-Specific Chimeric Antigen Receptorâ€“Modified Virus-Specific T Cells for Progressive Glioblastoma. <i>JAMA Oncology</i> , 2017, 3, 1094.	3.4	608
4	Heparanase promotes tumor infiltration and antitumor activity of CAR-redirectioned T lymphocytes. <i>Nature Medicine</i> , 2015, 21, 524-529.	15.2	588
5	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. <i>Blood</i> , 2014, 123, 3750-3759.	0.6	534
6	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. <i>Molecular Therapy</i> , 2017, 25, 2214-2224.	3.7	378
7	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3547-3557.	0.8	367
8	Activity of Broad-Spectrum T Cells as Treatment for Adv, EBV, CMV, BKV, and HHV6 Infections after HSCT. <i>Science Translational Medicine</i> , 2014, 6, 242ra83.	5.8	357
9	Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. <i>Blood</i> , 2009, 114, 4283-4292.	0.6	311
10	Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. <i>Blood</i> , 2009, 114, 1958-1967.	0.6	235
11	Transgenic Expression of IL15 Improves Antiglioma Activity of IL13RÎ±2-CAR T Cells but Results in Antigen Loss Variants. <i>Cancer Immunology Research</i> , 2017, 5, 571-581.	1.6	232
12	Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. <i>Blood</i> , 2014, 124, 2824-2833.	0.6	229
13	Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirectioned T Cells. <i>Cancer Discovery</i> , 2017, 7, 1238-1247.	7.7	204
14	Inducible caspase-9 suicide gene controls adverse effects from alloplete T cells after haploidentical stem cell transplantation. <i>Blood</i> , 2015, 125, 4103-4113.	0.6	188
15	InÂVivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkinâ€™s Lymphomas. <i>Molecular Therapy</i> , 2018, 26, 2727-2737.	3.7	180
16	Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. <i>Blood</i> , 2014, 123, 3895-3905.	0.6	161
17	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1128-1139.	0.8	137
18	No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. <i>Annals of Surgery</i> , 2019, 269, 20-27.	2.1	96

#	ARTICLE	IF	CITATIONS
19	CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. <i>Science Translational Medicine</i> , 2015, 7, 285ra63.	5.8	93
20	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 809-821.	1.9	77
21	Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13R $\alpha$ 2-positive Glioma. <i>Molecular Therapy</i> , 2016, 24, 354-363.	3.7	72
22	A Semiparametric Regression Cure Model for Interval-Censored Data. <i>Journal of the American Statistical Association</i> , 2009, 104, 1168-1178.	1.8	58
23	Loss of function of NCOR1 and NCOR2 impairs memory through a novel GABAergic hypothalamus $\alpha$ CA3 projection. <i>Nature Neuroscience</i> , 2019, 22, 205-217.	7.1	54
24	Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein $\alpha$ Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. <i>Cytotherapy</i> , 2011, 13, 976-986.	0.3	50
25	Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3008-3008.	0.8	44
26	T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor $\alpha$ Expressing T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 7340-7350.	3.2	32
27	Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10508-10508.	0.8	32
28	CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 860-870.	1.6	29
29	Predicting Liver Allograft Discard. <i>Transplantation</i> , 2018, 102, 1520-1529.	0.5	29
30	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. <i>Blood Advances</i> , 2019, 3, 2057-2068.	2.5	27
31	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2012, 120, 223-223.	0.6	25
32	High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1643-1650.	2.0	24
33	A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. <i>British Journal of Haematology</i> , 2015, 170, 118-122.	1.2	22
34	Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling. <i>Blood</i> , 2016, 128, 1851-1851.	0.6	22
35	Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 537-541.	2.0	21
36	A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3097-3097.	0.8	21

#	ARTICLE	IF	CITATIONS
37	The optimal timing of surgical resection in high-risk neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2016, 51, 1665-1669.	0.8	18
38	Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas. <i>Blood</i> , 2015, 126, 185-185.	0.6	18
39	LÃ©vy-driven non-Gaussian Ornstein-Uhlenbeck processes for degradation-based reliability analysis. <i>IIE Transactions</i> , 2016, 48, 993-1003.	2.1	17
40	Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation. <i>Blood</i> , 2013, 122, 140-140.	0.6	16
41	Reply to E.M. Poeschl et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e361-e363.	0.8	15
42	Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives—A Single-Center Experience, 2008 to 2016. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1424-1431.	2.0	15
43	ICOSL <sup>+</sup> plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	15
44	Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. <i>Blood</i> , 2020, 135, 1428-1437.	0.6	15
45	Generalized metabolic bone disease and fracture risk in Rothmund-Thomson syndrome. <i>Human Molecular Genetics</i> , 2017, 26, 3046-3055.	1.4	13
46	Waiting list outcomes in pediatric lung transplantation: Poor results for children listed in adult transplant programs. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1201-1208.	0.3	13
47	Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus. <i>Journal of Virology</i> , 2018, 92, .	1.5	13
48	Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. <i>Molecular Therapy</i> , 2016, 24, 736-745.	3.7	11
49	Poor outcomes for children on the wait list at low-volume kidney transplant centers in the United States. <i>Pediatric Nephrology</i> , 2017, 32, 669-678.	0.9	11
50	Low rate of infusional toxicity after expanded cord blood transplantation. <i>Cytotherapy</i> , 2014, 16, 1153-1157.	0.3	10
51	Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e99.	0.6	10
52	Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2572-2572.	0.8	10
53	Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 434.e23-434.e29.	0.8	7
54	Semiparametric Probit Models with Univariate and Bivariate Current-status Data. <i>Biometrics</i> , 2018, 74, 68-76.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00420.	1.3	6
56	Sample size calculations for prevalent cohort designs. <i>Statistical Methods in Medical Research</i> , 2017, 26, 280-291.	0.7	5
57	Using a monotone single-index model to stabilize the propensity score in missing data problems and causal inference. <i>Statistics in Medicine</i> , 2019, 38, 1442-1458.	0.8	5
58	Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF- $\beta$ to Patients with EBV-Associated Lymphomas. <i>Blood</i> , 2010, 116, 560-560.	0.6	5
59	Imputation for semiparametric transformation models with biased-sampling data. <i>Lifetime Data Analysis</i> , 2012, 18, 470-503.	0.4	4
60	Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00139.	1.3	4
61	Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5064-5064.	0.8	4
62	An oncology clinical trial design with randomization adaptive to both short- and long-term responses. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2015-2031.	0.7	3
63	Response to the Letter by Smith et al.. <i>Stem Cells</i> , 2009, 27, 1224-1225.	1.4	1
64	Analysis of NF- $\kappa$ B Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome—A Children's Oncology Group Study. <i>Lymphoma</i> , 2012, 2012, 1-12.	0.2	1
65	Coordinate Regulation of NF- $\kappa$ B Subunit Expression in EBV Negative, but Not EBV Positive, Pediatric Hodgkin's Lymphoma. <i>Blood</i> , 2008, 112, 521-521.	0.6	1
66	Coordinate Regulation of NF- $\kappa$ B Subunit Expression In Pediatric Hodgkin Lymphoma Patients with Rapid Early Response to Therapy, but Not Slow Early Response to Therapy. <i>Blood</i> , 2010, 116, 2680-2680.	0.6	1
67	Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. <i>Blood</i> , 2011, 118, 956-956.	0.6	1
68	The Transplant Index: A Novel Method to Predict Adult Liver Transplant Waitlist Outcomes. <i>Transplantation</i> , 2019, 103, 1152-1158.	0.5	0
69	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. <i>Blood</i> , 2008, 112, 230-230.	0.6	0
70	Risk and Therapeutic Outcomes in a Multiethnic Group of Acute Lymphoblastic Leukemia Patients Treated at a Large Public Hospital. <i>Blood</i> , 2008, 112, 3938-3938.	0.6	0
71	Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. <i>Blood</i> , 2008, 112, 3505-3505.	0.6	0
72	Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. <i>Blood</i> , 2009, 114, 3212-3212.	0.6	0

#	ARTICLE	IF	CITATIONS
73	QOL-58. ASSESSING FATIGUE EXPERIENCED BY PEDIATRIC PATIENTS WITH INTRACRANIAL NEOPLASMS. Neuro-Oncology, 2020, 22, iii441-iii441.	0.6	0
74	EPID-11. ESTABLISHING A BASELINE TIME-FRAME FOR SYMPTOM ONSET TO DEFINITIVE DIAGNOSIS FOR CHILDREN WITH NEWLY-DIAGNOSED CNS TUMORS: AN EXPANDED, MULTI-INSTITUTIONAL COLLABORATIVE STUDY. Neuro-Oncology, 2020, 22, iii320-iii321.	0.6	0